Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: A preliminary report of a phase I dose escalation trial from the carolina conformal therapy consortium

M. A. Socinski, L. B. Marks, J. Garst, G. S. Sibley, W. Blackstock, A. Turrisi, J. Herndon, S. Zhou, M. Anscher, J. Crawford, T. Shafman, J. Rosenman

Research output: Contribution to journalArticle

12 Scopus citations


The maximum tolerated dose of conformal radiation therapy delivered at 1.6 Gy bid is being assessed in patients with unresectable stage IIB-IIIB non-small cell lung cancer who have been treated with induction regimens consisting of carboplatin plus paclitaxel or carboplatin plus vinorelbine. Data from the early stages of this parallel phase I study show that the two induction regimens are similar in toxicity and that both induce partial responses in 45% of patients. Both regimens can be followed by conformal radiotherapy using an accelerated hyperfractionated schedule to a dose of at least 80 Gy without experiencing unacceptable toxicity. Key morbidity observed thus far has involved the esophagus. Further cohorts of patients will receive higher doses of conformal radiotherapy (in 6.4 Gy increments) until the maximum tolerated dose is reached.

Original languageEnglish (US)
Pages (from-to)20-24
Number of pages5
Issue numberSUPPL. 1
Publication statusPublished - Feb 26 2001



  • Carboplatin
  • Paclitaxel
  • TRT
  • Vinorelbine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this